Comparative analysis of the Sokal, Euro and European Treatment and Outcome Study score in prognostication of Indian chronic myeloid leukemia-chronic phase patients on imatinib

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

Introduction:

The ultimate goal for CML management is risk stratification of the patients to design the appropriate treatment approach. The Sokal, Euro and EUTOS risk scores were established to prognosticate the patients on therapy.

Aim:

To perform a comparative assessment of the Sokal, Euro and EUTOS prognostic score in Indian CML-CP patients on imatinib.

Methods:

This is a retrospective study performed in 260 Ph+ CML-CP patients who were administered oral imatinib (400 mg/day).

Results:

166/260 were males and 94/260 were females (M: F::1.6:1) with median age 35 years (range 20-70). 92 (35.38%), 125 (48.07%) and 43 (16.5%) patients were divided into low, intermediate and high risk Sokal score respectively. 102 (39.23%), 106 (40.76%) and 52 (20%) patients were discriminated into low, intermediate and high risk Euro score respectively. 210 (80.7%) and 50 (19.2%) patients were divided into low and high risk EUTOS score. Cumulative incidence of MMR for low, intermediate and high-risk Sokal score was 87%, 76% and 84% respectively ( P = 0.016). Incidence of MMR in low, intermediate and high-risk Euro score was 93%, 85% and 68% respectively ( P = 0.001). Incidence of MMR was 80 % and 81% for low and high risk EUTOS score ( P = 0.764). Both EFS and OS are significantly correlated with Sokal score ( P = 0.004, P = 0.007) and Euro score ( P = 0.009, P = 0.001) but not with EUTOS score ( P = 0.581, P = 0.927).

Conclusion:

The present study highlights the significant prognostic role of Sokal and Euro score in predicting the treatment outcome of the CML- CP patients on imatinib.

Related collections

Most cited references 27

Record: found
Abstract: found
Article: not found

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.

Giuseppe Saglio, Dong-Wook Kim, Philipp le Coutre … (2010)

Nilotinib has been shown to be a more potent inhibitor of BCR-ABL than imatinib. We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase. In this phase 3, randomized, open-label, multicenter study, we assigned 846 patients with chronic-phase Philadelphia chromosome-positive CML in a 1:1:1 ratio to receive nilotinib (at a dose of either 300 mg or 400 mg twice daily) or imatinib (at a dose of 400 mg once daily). The primary end point was the rate of major molecular response at 12 months. At 12 months, the rates of major molecular response for nilotinib (44% for the 300-mg dose and 43% for the 400-mg dose) were nearly twice that for imatinib (22%) (P<0.001 for both comparisons). The rates of complete cytogenetic response by 12 months were significantly higher for nilotinib (80% for the 300-mg dose and 78% for the 400-mg dose) than for imatinib (65%) (P<0.001 for both comparisons). Patients receiving either the 300-mg dose or the 400-mg dose of nilotinib twice daily had a significant improvement in the time to progression to the accelerated phase or blast crisis, as compared with those receiving imatinib (P=0.01 and P=0.004, respectively). No patient with progression to the accelerated phase or blast crisis had a major molecular response. Gastrointestinal and fluid-retention events were more frequent among patients receiving imatinib, whereas dermatologic events and headache were more frequent in those receiving nilotinib. Discontinuations due to aminotransferase and bilirubin elevations were low in all three study groups. Nilotinib at a dose of either 300 mg or 400 mg twice daily was superior to imatinib in patients with newly diagnosed chronic-phase Philadelphia chromosome-positive CML. (ClinicalTrials.gov number, NCT00471497.) 2010 Massachusetts Medical Society

0 comments Cited 370 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: found
Article: not found

Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.

Michele Baccarani, Jorge Cortés, Fabrizio Pane … (2009)

To review and update the European LeukemiaNet (ELN) recommendations for the management of chronic myeloid leukemia with imatinib and second-generation tyrosine kinase inhibitors (TKIs), including monitoring, response definition, and first- and second-line therapy. These recommendations are based on a critical and comprehensive review of the relevant papers up to February 2009 and the results of four consensus conferences held by the panel of experts appointed by ELN in 2008. Cytogenetic monitoring was required at 3, 6, 12, and 18 months. Molecular monitoring was required every 3 months. On the basis of the degree and the timing of hematologic, cytogenetic, and molecular results, the response to first-line imatinib was defined as optimal, suboptimal, or failure, and the response to second-generation TKIs was defined as suboptimal or failure. Initial treatment was confirmed as imatinib 400 mg daily. Imatinib should be continued indefinitely in optimal responders. Suboptimal responders may continue on imatinb, at the same or higher dose, or may be eligible for investigational therapy with second-generation TKIs. In instances of imatinib failure, second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.

0 comments Cited 239 times – based on 0 reviews      Review now

Bookmark

Record: found
Abstract: not found
Article: not found

The biology of chronic myeloid leukemia.

S Faderl, M Talpaz, Z Estrov … (1999)

0 comments Cited 225 times – based on 0 reviews      Review now

Bookmark

All references

Author and article information

Journal

Journal ID (nlm-ta): South Asian J Cancer

Journal ID (iso-abbrev): South Asian J Cancer

Journal ID (publisher-id): SAJC

Title: South Asian Journal of Cancer

Publisher: Medknow Publications & Media Pvt Ltd (India )

ISSN (Print): 2278-330X

ISSN (Electronic): 2278-4306

Publication date (Print): Oct-Dec 2018

Volume: 7

Issue: 4

Pages: 258-262

Affiliations

[1]Department of Hematology, All India Institute of Medical Sciences, New Delhi, India

Author notes

Correspondence to: Dr. Renu Saxena, E-mail: renusaxena@ 123456outlook.com

Article

Publisher ID: SAJC-7-258

DOI: 10.4103/sajc.sajc_244_17

PMC ID: 6190386

PubMed ID: 30430096

SO-VID: ccebfe4e-446a-4c47-bfb3-529aba053181

License:

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

History

Comments

Comment on this article

scite_

Smart Citations

Citing PublicationsSupportingMentioningContrasting

View Citations

See how this article has been cited at scite.ai

scite shows how a scientific paper has been cited by providing the context of the citation, a classification describing whether it supports, mentions, or contrasts the cited claim, and a label indicating in which section the citation was made.